Wei Zheng

List of Publications by Year
in descending order

234 papers	12,082 citations	30047 54 h-index	37183 96 g-index
273 all docs	273 docs citations	273 times ranked	19038 citing authors

#	Article	IF	Citations
1	SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening. ACS Pharmacology and Translational Science, 2022, 5, 8-19.	2.5	5
2	Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors. MBio, 2022, 13, e0323821.	1.8	11
3	A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry. SLAS Discovery, 2022, 27, 86-94.	1.4	16
4	iPS-derived neural stem cells for disease modeling and evaluation of therapeutics for mucopolysaccharidosis type II. Experimental Cell Research, 2022, 412, 113007.	1.2	5
5	c-Abl Activation Linked to Autophagy-Lysosomal Dysfunction Contributes to Neurological Impairment in Niemann-Pick Type A Disease. Frontiers in Cell and Developmental Biology, 2022, 10, 844297.	1.8	9
6	Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinsonâ€™s Disease: Pathogenesis and Therapeutic Implications. Frontiers in Aging Neuroscience, 2022, 14, 851135.	1.7	7
7	Efficient Identification of Anti-SARS-CoV-2 Compounds Using Chemical Structure- and Biological Activity-Based Modeling. Journal of Medicinal Chemistry, 2022, 65, 4590-4599.	2.9	15
8	Repurposing drugs as COVID-19 therapies: A toxicity evaluation. Drug Discovery Today, 2022, 27, 1983-1993.	3.2	16
9	Mitoxantrone modulates a heparan sulfate-spike complex to inhibit SARS-CoV-2 infection. Scientific Reports, 2022, 12, 6294.	1.6	8
10	Graph Convolutional Network-Based Screening Strategy for Rapid Identification of SARS-CoV-2 Cell-Entry Inhibitors. Journal of Chemical Information and Modeling, 2022, 62, 1988-1997.	2.5	1
11	Enteral extended biliary stents versus conventional plastic biliary stents for the treatment of extrahepatic malignant biliary obstruction: a single-center prospective randomized controlled study. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 8202-8213.	1.3	1
12	Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19. ACS Infectious Diseases, 2022, 8, 1191-1203.	1.8	4
13	Discovery and Optimization of Pyrrolopyrimidine Derivatives as Selective Disruptors of the Perinucleolar Compartment, a Marker of Tumor Progression toward Metastasis. Journal of Medicinal Chemistry, 2022, 65, 8303-8331.	2.9	4
14	Endoclip papillaplasty restores sphincter of Oddi function: Pilot study. Digestive Endoscopy, 2021, 33, 962-969.	1.3	2
15	Effects of SARSâ€CoVâ€2 mutations on protein structures and intraviral proteinâ€“protein interactions. Journal of Medical Virology, 2021, 93, 2132-2140.	2.5	85
16	Synergistic and Antagonistic Drug Combinations against SARS-CoV-2. Molecular Therapy, 2021, 29, 873-885.	3.7	78
17	The SARS-CoV-2 Cytopathic Effect Is Blocked by Lysosome Alkalizing Small Molecules. ACS Infectious Diseases, 2021, 7, 1389-1408.	1.8	74
18	Structural interaction between DISC1 and ATF4 underlying transcriptional and synaptic dysregulation in an iPSC model of mental disorders. Molecular Psychiatry, 2021, 26, 1346-1360.	4.1	22

#	Article	IF	Citations
19	Drug Combinations. , 2021, , .		0
20	An Integrated Systems Biology Approach Identifies the Proteasome as A Critical Host Machinery for ZIKV and DENV Replication. Genomics, Proteomics and Bioinformatics, 2021, 19, 108-122.	3.0	7
21	Biological activity-based modeling identifies antiviral leads against SARS-CoV-2. Nature Biotechnology, 2021, 39, 747-753.	9.4	38
22	Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics. Scientific Reports, 2021, 11, 6725.	1.6	25
23	Identification of Antifungal Compounds against Multidrug-Resistant Candida auris Utilizing a High-Throughput Drug-Repurposing Screen. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	19
24	SENP1-mediated deSUMOylation of JAK2 regulates its kinase activity and platinum drug resistance. Cell Death and Disease, 2021, 12, 341.	2.7	13
25	Generation of an induced pluripotent stem cell line (TRNDi030-A) from a patient with Farber disease carrying a homozygous p. Y36C (c. 107 A>G) mutation in ASAH1. Stem Cell Research, 2021, 53, 102387.	0.3	2
26	Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection. Bioorganic and Medicinal Chemistry Letters, 2021, 40, 127906.	1.0	15
27	Viral Proteases as Targets for Coronavirus Disease 2019 Drug Development. Journal of Pharmacology and Experimental Therapeutics, 2021, 378, 166-172.	1.3	19
28	Highâ€throughput screening assays for SARSâ€CoVâ€2 drug development: Current status and future directions. Drug Discovery Today, 2021, 26, 2439-2444.	3.2	21
29	Generation of Alagille syndrome derived induced pluripotent stem cell line carrying heterozygous mutation in the JAGGED-1 gene at splicing site (Chr20: 10,629,709C>A) before exon 11. Stem Cell Research, 2021, 53, 102366.	0.3	2
30	Drug combination therapy for emerging viral diseases. Drug Discovery Today, 2021, 26, 2367-2376.	3.2	65
31	Enrichment of NPC1-deficient cells with the lipid LBPA stimulates autophagy, improves lysosomal function, and reduces cholesterol storage. Journal of Biological Chemistry, 2021, 297, 100813.	1.6	29
32	Generation of an induced pluripotent stem cell line (TRNDi031-A) from a patient with Alagille syndrome type 1 carrying a heterozygous p. C312X (c. 936ÂTÂ>ÂA) mutation in JAGGED-1. Stem Cell Research, 2021, 54, 102447.	0.3	1
33	Discovery of Small Molecule Entry Inhibitors Targeting the Fusion Peptide of SARS-CoV-2 Spike Protein. ACS Medicinal Chemistry Letters, 2021, 12, 1267-1274.	1.3	16
34	Generation of an induced pluripotent stem cell line (TRNDi012-B) from Fibrodysplasia Ossificans Progressiva (FOP) patient carrying a heterozygous mutation c. 617GÂ>ÂA in the ACVR1 gene. Stem Cell Research, 2021, 54, 102424.	0.3	0
35	An induced pluripotent stem cell line (NCATS-CL9075) from a patient carrying compound heterozygote mutations, p.R390P and p.L318P, in the NGLY1 gene. Stem Cell Research, 2021, 54, 102400.	0.3	0
36	Therapeutics Development for Alagille Syndrome. Frontiers in Pharmacology, 2021, 12, 704586.	1.6	7

#	Article	IF	Citations
37	Protein structural features predict responsiveness to pharmacological chaperone treatment for three lysosomal storage disorders. PLoS Computational Biology, 2021, 17, e1009370.	1.5	4
38	Hybrid In Silico Approach Reveals Novel Inhibitors of Multiple SARS-CoV-2 Variants. ACS Pharmacology and Translational Science, 2021, 4, 1675-1688.	2.5	6
39	Generation of two gene corrected human isogenic iPSC lines (NCATS-CL6104 and NCATS-CL6105) from a patient line (NCATS-CL6103) carrying a homozygous p.R401X mutation in the NGLY1 gene using CRISPR/Cas9. Stem Cell Research, 2021, 56, 102554.	0.3	1
40	Disease modeling for Mucopolysaccharidosis type IIIB using patient derived induced pluripotent stem cells. Experimental Cell Research, 2021, 407, 112785.	1.2	3
41	Modeling CNS Involvement in Pompe Disease Using Neural Stem Cells Generated from Patient-Derived Induced Pluripotent Stem Cells. Cells, 2021, 10, 8.	1.8	13
42	Identification of potent SENP1 inhibitors that inactivate SENP1/JAK2/STAT signaling pathway and overcome platinum drug resistance in ovarian cancer. Clinical and Translational Medicine, 2021, 11, e649.	1.7	6
43	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. Antiviral Research, 2020, 173, 104667.	1.9	11
44	Four induced pluripotent stem cell lines (TRNDi021-C, TRNDi023-D, TRNDi024-D and TRNDi025-A) generated from fibroblasts of four healthy individuals. Stem Cell Research, 2020, 49, 102011.	0.3	2
45	Development of a High-Throughput Homogeneous AlphaLISA Drug Screening Assay for the Detection of SARS-CoV-2 Nucleocapsid. ACS Pharmacology and Translational Science, 2020, 3, 1233-1241.	2.5	10
46	RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery. SLAS Discovery, 2020, 25, 1141-1151.	1.4	131
47	Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro. Cell Discovery, 2020, 6, 80.	3.1	172
48	Drug Discovery Strategies for SARS-CoV-2. Journal of Pharmacology and Experimental Therapeutics, 2020, 375, 127-138.	1.3	83
49	Human recombinant lysosomal <scp>Î²â€Hexosaminidases</scp> produced in <scp>Pichia pastoris</scp> efficiently reduced lipid accumulation in <scp>Tayâ€Sachs</scp> fibroblasts. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2020, 184, 885-895.	0.7	7
50	Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles. ACS Pharmacology and Translational Science, 2020, 3, 1165-1175.	2.5	94
51	Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening. ACS Pharmacology and Translational Science, 2020, 3, 1008-1016.	2.5	162
52	Cell-Based No-Wash Fluorescence Assays for Compound Screens Using a Fluorescence Cytometry Plate Reader. Journal of Pharmacology and Experimental Therapeutics, 2020, 374, 500-511.	1.3	1
53	Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium. Cell Stem Cell, 2020, 27, 937-950.e9.	5.2	314
54	Torin 2 Derivative, NCATS-SM3710, Has Potent Multistage Antimalarial Activity through Inhibition of P. falciparum Phosphatidylinositol 4-Kinase (Pfâ€PI4KIIIÎ²). ACS Pharmacology and Translational Science, 2020, 3, 948-964.	2.5	19

#	Article	IF	Citations
55	Zika Virus-Induced Neuronal Apoptosis via Increased Mitochondrial Fragmentation. Frontiers in Microbiology, 2020, 11, 598203.	1.5	27
56	An induced pluripotent stem cell line (TRNDi001-D) from a Niemann-Pick disease type C1 (NPC1) patient carrying a homozygous p. I1061T (c. 3182T>C) mutation in the NPC1 gene. Stem Cell Research, 2020, 44, 101737.	0.3	4
57	Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2. Frontiers in Pharmacology, 2020, 11, 592737.	1.6	69
58	Advancing precision medicine with personalized drug screening. Drug Discovery Today, 2019, 24, 272-278.	3.2	27
59	ERK Regulates HIF1Î±-Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer. Clinical Cancer Research, 2019, 25, 5947-5960.	3.2	37
60	An induced pluripotent stem cell line (TRNDi010-C) from a patient carrying a homozygous p.R401X mutation in the NGLY1 gene. Stem Cell Research, 2019, 39, 101496.	0.3	2
61	Improving therapy of severe infections through drug repurposing of synergistic combinations. Current Opinion in Pharmacology, 2019, 48, 92-98.	1.7	51
62	Induced pluripotent stem cells for neural drug discovery. Drug Discovery Today, 2019, 24, 992-999.	3.2	63
63	Î´-Tocopherol Effect on Endocytosis and Its Combination with Enzyme Replacement Therapy for Lysosomal Disorders: A New Type of Drug Interaction?. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 823-833.	1.3	6
64	Pharmacological analysis of CFTR variants of cystic fibrosis using stem cell-derived organoids. Drug Discovery Today, 2019, 24, 2126-2138.	3.2	15
65	An induced pluripotent stem cell line (TRNDi009-C) from a Niemann-Pick disease type A patient carrying a heterozygous p.L302P (c.905 T>C) mutation in the SMPD1 gene. Stem Cell Research, 2019, 38, 101461.	0.3	10
66	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA. Journal of Medicinal Chemistry, 2019, 62, 6175-6189.	2.9	26
67	Generation of an induced pluripotent stem cell line (TRNDi008-A) from a Hunter syndrome patient carrying a hemizygous 208insC mutation in the IDS gene. Stem Cell Research, 2019, 37, 101451.	0.3	5
68	17-Hydroxy Wortmannin Restores TRAIL's Response by Ameliorating Increased Beclin 1 Level and Autophagy Function in TRAIL-Resistant Colon Cancer Cells. Molecular Cancer Therapeutics, 2019, 18, 1265-1277.	1.9	6
69	Generation of an induced pluripotent stem cell line (TRNDi004-I) from a Niemann-Pick disease type B patient carrying a heterozygous mutation of p.L43_A44delLA in the SMPD1 gene. Stem Cell Research, 2019, 37, 101436.	0.3	3
70	A human induced pluripotent stem cell line (TRNDi007-B) from an infantile onset Pompe patient carrying p.R854X mutation in the GAA gene. Stem Cell Research, 2019, 37, 101435.	0.3	9
71	High-Throughput Zika Viral Titer Assay for Rapid Screening of Antiviral Drugs. Assay and Drug Development Technologies, 2019, 17, 128-139.	0.6	8
72	An induced pluripotent stem cell line (TRNDi006-A) from a MPS IIIB patient carrying homozygous mutation of p.Glu153Lys in the NAGLU gene. Stem Cell Research, 2019, 37, 101427.	0.3	4

#	Article	IF	Citations
73	Generation of an induced pluripotent stem cell line (TRNDi005-A) from a Mucopolysaccharidosis Type IVA (MPS IVA) patient carrying compound heterozygous p.R61W and p.WT405del mutations in the GALNS gene. Stem Cell Research, 2019, 36, 101408.	0.3	5
74	Quantitative Chemotherapeutic Profiling of Gynecologic Cancer Cell Lines Using Approved Drugs and Bioactive Compounds. Translational Oncology, 2019, 12, 441-452.	1.7	14
75	Generation of an induced pluripotent stem cell line (TRNDi003-A) from a Noonan syndrome with multiple lentigines (NSML) patient carrying a p.Q510P mutation in the PTPN11 gene. Stem Cell Research, 2019, 34, 101374.	0.3	10
76	Generation of an induced pluripotent stem cell line (TRNDi002-B) from a patient carrying compound heterozygous p.Q208X and p.G310G mutations in the NGLY1 gene. Stem Cell Research, 2019, 34, 101362.	0.3	7
77	Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance. Oncogene, 2018, 37, 3981-3997.	2.6	31
78	Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 3582-3594.	2.9	32
79	Astrocytes as targets for drug discovery. Drug Discovery Today, 2018, 23, 673-680.	3.2	43
80	Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1/PPT1) and late infantile (CLN2/TPP1) neuronal ceroid lipofuscinoses. Orphanet Journal of Rare Diseases, 2018, 13, 54.	1.2	31
81	DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer. Cancer Letters, 2018, 428, 104-116.	3.2	60
82	Drug repurposing screens and synergistic drugâ€combinations for infectious diseases. British Journal of Pharmacology, 2018, 175, 181-191.	2.7	181
83	Repurposing a novel parathyroid hormone analogue to treat hypoparathyroidism. British Journal of Pharmacology, 2018, 175, 262-271.	2.7	15
84	Quantitative highâ€throughput screening identifies cytoprotective molecules that enhance SUMO conjugation via the inhibition of SUMOâ€specific protease (SENP)2. FASEB Journal, 2018, 32, 1677-1691.	0.2	29
85	Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space. ACS Central Science, 2018, 4, 1727-1741.	5.3	32
86	â€œReal-Timeâ€•High-Throughput Drug and Synergy Testing for Multidrug-Resistant Bacterial Infection: A Case Report. Frontiers in Medicine, 2018, 5, 267.	1.2	4
87	Neural stem cells for disease modeling and evaluation of therapeutics for Tay-Sachs disease. Orphanet Journal of Rare Diseases, 2018, 13, 152.	1.2	34
88	Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis. Science Translational Medicine, 2018, 10, .	5.8	55
89	Optimization of the first small-molecule relaxin/insulin-like family peptide receptor (RXFP1) agonists: Activation results in an antifibrotic gene expression profile. European Journal of Medicinal Chemistry, 2018, 156, 79-92.	2.6	9
90	Small Molecules Identified from a Quantitative Drug Combinational Screen Resensitize Cisplatin's Response in Drug-Resistant Ovarian Cancer Cells. Translational Oncology, 2018, 11, 1053-1064.	1.7	8

#	Article	IF	Citations
91	Patient iPSC-derived neural stem cells exhibit phenotypes in concordance with the clinical severity of mucopolysaccharidosis I. Human Molecular Genetics, 2018, 27, 3612-3626.	1.4	23
92	Pluripotent Stem Cell Platforms for Drug Discovery. Trends in Molecular Medicine, 2018, 24, 805-820.	3.5	33
93	Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry. Cell Discovery, 2018, 4, 31.	3.1	128
94	Repurposing Screen Identifies Unconventional Drugs With Activity Against Multidrug Resistant Acinetobacter baumannii. Frontiers in Cellular and Infection Microbiology, 2018, 8, 438.	1.8	37
95	Zika Virus: Origins, Pathological Action, and Treatment Strategies. Frontiers in Microbiology, 2018, 9, 3252.	1.5	58
96	Drugging SUMOylation for neuroprotection and oncotherapy. Neural Regeneration Research, 2018, 13, 415.	1.6	9
97	Methyl-Î²-cyclodextrin restores impaired autophagy flux in Niemann-Pick C1-deficient cells through activation of AMPK. Autophagy, 2017, 13, 1435-1451.	4.3	73
98	Novel lead structures with both Plasmodium falciparum gametocytocidal and asexual blood stage activity identified from high throughput compound screening. Malaria Journal, 2017, 16, 147.	0.8	14
99	Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. Journal of Medicinal Chemistry, 2017, 60, 6364-6383.	2.9	12
100	Analytical Characterization of Methyl-Î²-Cyclodextrin for Pharmacological Activity to Reduce Lysosomal Cholesterol Accumulation in Niemann-Pick Disease Type C1 Cells. Assay and Drug Development Technologies, 2017, 15, 154-166.	0.6	17
101	Efficient Synthesis of 1,9-Substituted Benzo[h][1,6]naphthyridin-2(1H)-ones and Evaluation of their Plasmodium falciparum Gametocytocidal Activities. ACS Combinatorial Science, 2017, 19, 748-754.	3.8	7
102	Identification of 4-phenylquinolin-2(1H)-one as a specific allosteric inhibitor of Akt. Scientific Reports, 2017, 7, 11673.	1.6	5
103	Drug discovery and development for rare genetic disorders. American Journal of Medical Genetics, Part A, 2017, 173, 2307-2322.	0.7	64
104	Neural stem cells for disease modeling of Wolman disease and evaluation of therapeutics. Orphanet Journal of Rare Diseases, 2017, 12, 120.	1.2	18
105	Synergistic drug combination effectively blocks Ebola virus infection. Antiviral Research, 2017, 137, 165-172.	1.9	75
106	Targeting Wolman Disease and Cholesteryl Ester Storage Disease: Disease Pathogenesis and Therapeutic Development. Current Chemical Genomics and Translational Medicine, 2017, 11, 1-18.	4.3	42
107	Dietary Fat Intake and Lung Cancer Risk: A Pooled Analysis. Journal of Clinical Oncology, 2017, 35, 3055-3064.	0.8	52
108	Inhibition of PIP4KÎ³ ameliorates the pathological effects of mutant huntingtin protein. ELife, 2017, 6, .	2.8	49

#	Article	IF	Citations
109	Treatment Paradigms for Retinal and Macular Diseases Using 3-D Retina Cultures Derived From Human Reporter Pluripotent Stem Cell Lines. , 2016, 57, ORSFl1.		35
110	A High-Throughput, Multi-Cell Phenotype Assay for the Identification of Novel Inhibitors of Chemotaxis/Migration. Scientific Reports, 2016, 6, 22273.	1.6	15
111	Drug combination therapy increases successful drug repositioning. Drug Discovery Today, 2016, 21, 1189-1195.	3.2	284
112	High-Throughput Phenotypic Screening of Human Astrocytes to Identify Compounds That Protect Against Oxidative Stress. Stem Cells Translational Medicine, 2016, 5, 613-627.	1.6	31
113	In vitro evaluation of imidazo[4,5 -c]quinolin-2-ones as gametocytocidal antimalarial agents. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2907-2911.	1.0	10
114	Induced Pluripotent Stem Cells for Disease Modeling and Evaluation of Therapeutics for Niemann-Pick Disease Type A. Stem Cells Translational Medicine, 2016, 5, 1644-1655.	1.6	29
115	Disease models for the development of therapies for lysosomal storage diseases. Annals of the New York Academy of Sciences, 2016, 1371, 15-29.	1.8	34
116	Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nature Medicine, 2016, 22, 1101-1107.	15.2	581
117	Molecular signatures associated with ZIKV exposure in human cortical neural progenitors. Nucleic Acids Research, 2016, 44, 8610-8620.	6.5	155
118	One-Step Seeding of Neural Stem Cells with Vitronectin-Supplemented Medium for High-Throughput Screening Assays. Journal of Biomolecular Screening, 2016, 21, 1112-1124.	2.6	11
119	A New Glucocerebrosidase Chaperone Reduces Â-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism. Journal of Neuroscience, 2016, 36, 7441-7452.	1.7	189
120	Rapid antimicrobial susceptibility test for identification of new therapeutics and drug combinations against multidrug-resistant bacteria. Emerging Microbes and Infections, 2016, 5, 1-11.	3.0	59
121	Identification of Multiple Cryptococcal Fungicidal Drug Targets by Combined Gene Dosing and Drug Affinity Responsive Target Stability Screening. MBio, 2016, 7, .	1.8	19
122	High throughput cell-based assay for identification of glycolate oxidase inhibitors as a potential treatment for Primary Hyperoxaluria Type 1. Scientific Reports, 2016, 6, 34060.	1.6	20
123	Rho GTPases: RAC1 polymorphisms affected platinum-based chemotherapy toxicity in lung cancer patients. Cancer Chemotherapy and Pharmacology, 2016, 78, 249-258.	1.1	20
124	A novel quantitative high-throughput screen identifies drugs that both activate SUMO conjugation via the inhibition of microRNAs 182 and 183 and facilitate neuroprotection in a model of oxygen and glucose deprivation. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 426-441.	2.4	34
125	Maduramicin Rapidly Eliminates Malaria Parasites and Potentiates the Gametocytocidal Activity of the Pyrazoleamide PA21A050. Antimicrobial Agents and Chemotherapy, 2016, 60, 1492-1499.	1.4	23
126	Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. Journal of Medicinal Chemistry, 2016, 59, 841-853.	2.9	30

#	Article	IF	Citations
127	ML372 blocks SMN ubiquitination and improves spinal muscular atrophy pathology in mice. JCI Insight, 2016, 1, e88427.	2.3	16
128	Elabela-Apelin Receptor Signaling Pathway is Functional in Mammalian Systems. Scientific Reports, 2015, 5, 8170.	1.6	156
129	A cost-effective and efficient reprogramming platform for large-scale production of integration-free human induced pluripotent stem cells in chemically defined culture. Scientific Reports, 2015, 5, 11319.	1.6	96
130	Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia. Cancer Cell, 2015, 27, 864-876.	7.7	265
131	High-Throughput Screening to Identify Compounds That Increase Fragile X Mental Retardation Protein Expression in Neural Stem Cells Differentiated From Fragile X Syndrome Patient-Derived Induced Pluripotent Stem Cells. Stem Cells Translational Medicine, 2015, 4, 800-808.	1.6	70
132	Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. Breast Cancer Research, 2015, 17, 59.	2.2	61
133	Mitochondrial DNA damage by bleomycin induces AML cell death. Apoptosis: an International Journal on Programmed Cell Death, 2015, 20, 811-820.	2.2	20
134	ERK and Î²-Arrestin Interaction: A Converging Point of Signaling Pathways for Multiple Types of Cell Surface Receptors. Journal of Biomolecular Screening, 2015, 20, 341-349.	2.6	29
135	High-Throughput Viability Assay Using an Autonomously Bioluminescent Cell Line with a Bacterial Lux Reporter. Journal of the Association for Laboratory Automation, 2015, 20, 164-174.	2.8	21
136	Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. Science Translational Medicine, 2015, 7, 282ra49.	5.8	118
137	Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay. Antiviral Research, 2015, 124, 20-29.	1.9	9
138	High-Throughput Screening, Discovery, and Optimization To Develop a Benzofuran Class of Hepatitis C Virus Inhibitors. ACS Combinatorial Science, 2015, 17, 641-652.	3.8	23
139	Structural Basis for Inactivation of Giardia lamblia Carbamate Kinase by Disulfiram. Journal of Biological Chemistry, 2014, 289, 10502-10509.	1.6	51
140	Niemannâ€“Pick Disease Type C: Induced Pluripotent Stem Cellâ€“Derived Neuronal Cells for Modeling Neural Disease and Evaluating Drug Efficacy. Journal of Biomolecular Screening, 2014, 19, 1164-1173.	2.6	73
141	Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerging Microbes and Infections, 2014, 3, 1-7.	3.0	200
142	Macrophage Models of Gaucher Disease for Evaluating Disease Pathogenesis and Candidate Drugs. Science Translational Medicine, 2014, 6, 240ra73.	5.8	94
143	A Phenotypic Compound Screening Assay for Lysosomal Storage Diseases. Journal of Biomolecular Screening, 2014, 19, 168-175.	2.6	51
144	High-content screening identifies small molecules that remove nuclear foci, affect MBNL distribution and CELF1 protein levels via a PKC-independent pathway in myotonic dystrophy cell lines. Human Molecular Genetics, 2014, 23, 1551-1562.	1.4	69

#	Article	IF	Citations
145	Lomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects. Nucleic Acids Research, 2014, 42, 6591-6602.	6.5	46
146	Discovery, Optimization, and Characterization of Novel D₂ Dopamine Receptor Selective Antagonists. Journal of Medicinal Chemistry, 2014, 57, 3450-3463.	2.9	27
147	Discovery of Novel Antigiardiasis Drug Candidates. Antimicrobial Agents and Chemotherapy, 2014, 58, 7303-7311.	1.4	33
148	A High-Throughput Screening Assay for Fungicidal Compounds against Cryptococcus neoformans. Journal of Biomolecular Screening, 2014, 19, 270-277.	2.6	27
149	Novel Cell-Based Hepatitis C Virus Infection Assay for Quantitative High-Throughput Screening of Anti-Hepatitis C Virus Compounds. Antimicrobial Agents and Chemotherapy, 2014, 58, 995-1004.	1.4	30
150	Inhibition of HERG potassium channels by domiphen bromide and didecyl dimethylammonium bromide. European Journal of Pharmacology, 2014, 737, 202-209.	1.7	5
151	Chemical signatures and new drug targets for gametocytocidal drug development. Scientific Reports, 2014, 4, 3743.	1.6	89
152	A High Throughput Screening Assay System for the Identification of Small Molecule Inhibitors of gsp. PLoS ONE, 2014, 9, e90766.	1.1	16
153	Collaborative Development of 2-Hydroxypropyl-β-Cyclodextrin for the Treatment of Niemann-Pick Type C1 Disease. Current Topics in Medicinal Chemistry, 2014, 14, 330-339.	1.0	108
154	A high-throughput screening assay for assessing the viability of Cryptococcus neoformans under nutrient starvation conditions. Analytical and Bioanalytical Chemistry, 2013, 405, 6823-6829.	1.9	8
155	Phenotypic screens as a renewed approach for drug discovery. Drug Discovery Today, 2013, 18, 1067-1073.	3.2	363
156	Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. Nature Communications, 2013, 4, 2044.	5.8	76
157	Identification and optimization of small-molecule agonists of the human relaxin hormone receptor RXFP1. Nature Communications, 2013, 4, 1953.	5.8	54
158	Structureâ€“Activity Relationship of Imidazopyridinium Analogues as Antagonists of Neuropeptide S Receptor. Journal of Medicinal Chemistry, 2013, 56, 9045-9056.	2.9	18
159	A quantitative high throughput assay for identifying gametocytocidal compounds. Molecular and Biochemical Parasitology, 2013, 188, 20-25.	0.5	45
160	Mechanism of HERG potassium channel inhibition by tetra-n-octylammonium bromide and benzethonium chloride. Toxicology and Applied Pharmacology, 2013, 267, 155-166.	1.3	14
161	A Novel Brain Penetrant NPS Receptor Antagonist, NCGC00185684, Blocks Alcohol-Induced ERK-Phosphorylation in the Central Amygdala and Decreases Operant Alcohol Self-Administration in Rats. Journal of Neuroscience, 2013, 33, 10132-10142.	1.7	27
162	Identification of Small-Molecule Agonists of Human Relaxin Family Receptor 1 (RXFP1) by Using a Homogenous Cell-Based cAMP Assay. Journal of Biomolecular Screening, 2013, 18, 670-677.	2.6	27

#	Article	IF	Citations
163	An Alternative Direct Compound Dispensing Method Using the HP D300 Digital Dispenser. Journal of the Association for Laboratory Automation, 2013, 18, 367-374.	2.8	22
164	Identification of a Selective Small-Molecule Inhibitor Series Targeting the Eyes Absent 2 (Eya2) Phosphatase Activity. Journal of Biomolecular Screening, 2013, 18, 85-96.	2.6	33
165	Rapid Identification of Antifungal Compounds against Exserohilum rostratum Using High Throughput Drug Repurposing Screens. PLoS ONE, 2013, 8, e70506.	1.1	23
166	A High-Throughput Screening Assay for Determining Cellular Levels of Total Tau Protein. Current Alzheimer Research, 2013, 10, 679-687.	0.7	25
167	Evaluation of Cholesterol Reduction Activity of Methyl-Î²-cyclodextrin Using Differentiated Human Neurons and Astrocytes. Journal of Biomolecular Screening, 2012, 17, 1243-1251.	2.6	20
168	Î´-Tocopherol Reduces Lipid Accumulation in Niemann-Pick Type C1 and Wolman Cholesterol Storage Disorders. Journal of Biological Chemistry, 2012, 287, 39349-39360.	1.6	107
169	Plasma and Tissue Concentrations of Î±-Tocopherol and Î´-Tocopherol Following High Dose Dietary Supplementation in Mice. Nutrients, 2012, 4, 467-490.	1.7	20
170	Non-iminosugar glucocerebrosidase small molecule chaperones. MedChemComm, 2012, 3, 56-60.	3.5	22
171	Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1â€“CBFÎ² interaction. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14592-14597.	3.3	108
172	Discovery of a Novel Noniminosugar Acid Î± Glucosidase Chaperone Series. Journal of Medicinal Chemistry, 2012, 55, 7546-7559.	2.9	27
173	Discovery, Structureâ€“Activity Relationship, and Biological Evaluation of Noninhibitory Small Molecule Chaperones of Glucocerebrosidase. Journal of Medicinal Chemistry, 2012, 55, 5734-5748.	2.9	113
174	A high-throughput sphingomyelinase assay using natural substrate. Analytical and Bioanalytical Chemistry, 2012, 404, 407-414.	1.9	7
175	A high throughput glucocerebrosidase assay using the natural substrate glucosylceramide. Analytical and Bioanalytical Chemistry, 2012, 402, 731-739.	1.9	31
176	Two high-throughput screening assays for aberrant RNAâ€“protein interactions in myotonic dystrophy type 1. Analytical and Bioanalytical Chemistry, 2012, 402, 1889-1898.	1.9	49
177	High Throughput Screening for Small Molecule Therapy for Gaucher Disease Using Patient Tissue as the Source of Mutant Glucocerebrosidase. PLoS ONE, 2012, 7, e29861.	1.1	62
178	High-Throughput Multiplexed Quantitation of Protein Aggregation and Cytotoxicity in a Huntingtonâ€™s Disease Model. Current Chemical Genomics, 2012, 6, 79-86.	2.0	22
179	A Homogenous Luminescence Assay Reveals Novel Inhibitors for Giardia LambliaCarbamate Kinase. Current Chemical Genomics, 2012, 6, 93-102.	2.0	16
180	The synthesis and evaluation of dihydroquinazolin-4-ones and quinazolin-4-ones as thyroid stimulating hormone receptor agonists. MedChemComm, 2011, 2, 1016.	3.5	9

#	Article	IF	Citations
181	Discovery, Synthesis, and Biological Evaluation of Novel SMN Protein Modulators. Journal of Medicinal Chemistry, 2011, 54, 6215-6233.	2.9	38
182	Evaluation of Quinazoline Analogues as Glucocerebrosidase Inhibitors with Chaperone Activity. Journal of Medicinal Chemistry, 2011, 54, 1033-1058.	2.9	59
183	Novel Patient Cell-Based HTS Assay for Identification of Small Molecules for a Lysosomal Storage Disease. PLoS ONE, 2011, 6, e29504.	1.1	11
184	Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels. Toxicology and Applied Pharmacology, 2011, 252, 250-258.	1.3	34
185	Phosphodiesterase 4 inhibitors enhance sexual pleasure-seeking activity in rodents. Pharmacology Biochemistry and Behavior, 2011, 98, 349-355.	1.3	2
186	High-ThroughputGiardia lambliaViability Assay Using Bioluminescent ATP Content Measurements. Antimicrobial Agents and Chemotherapy, 2011, 55, 667-675.	1.4	43
187	Evaluation of 2-thioxo-2,3,5,6,7,8-hexahydropyrimido[4,5-d]pyrimidin-4(1H)-one analogues as GAA activators. European Journal of Medicinal Chemistry, 2010, 45, 1880-1897.	2.6	24
188	Fabry Disease â€“ Current Treatment and New Drug Development. Current Chemical Genomics, 2010, 4, 50-56.	2.0	42
189	High Throughput Screening for Inhibitors of Alpha-Galactosidase. Current Chemical Genomics, 2010, 4, 67-73.	2.0	16
190	Selective Modulation of Gq/Gs pathways by Naphtho Pyrano Pyrimidines As Antagonists of the Neuropeptide S Receptor. ACS Chemical Neuroscience, 2010, 1, 559-574.	1.7	25
191	A Multiplex Calcium Assay for Identification of GPCR Agonists and Antagonists. Assay and Drug Development Technologies, 2010, 8, 362-374.	0.6	29
192	Small Molecule Drug Discovery for Fabry Disease. , 2010, , 163-177.		0
193	The Pilot Phase of the NIH Chemical Genomics Center. Current Topics in Medicinal Chemistry, 2009, 9, 1181-1193.	1.0	28
194	An AlphaScreenâ„¢-Based High-Throughput Screen to Identify Inhibitors of Hsp90-Cochaperone Interaction. Journal of Biomolecular Screening, 2009, 14, 273-281.	2.6	47
195	Small-molecule agonists for the thyrotropin receptor stimulate thyroid function in human thyrocytes and mice. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12471-12476.	3.3	102
196	Cardiac Glycosides Inhibit p53 Synthesis by a Mechanism Relieved by Src or MAPK Inhibition. Cancer Research, 2009, 69, 6556-6564.	0.4	105
197	Automated High-Content Screening for Compounds That Disassemble the Perinucleolar Compartment. Journal of Biomolecular Screening, 2009, 14, 1045-1053.	2.6	25
198	Synthesis and characterization of a new fluorogenic substrate for alpha-galactosidase. Analytical and Bioanalytical Chemistry, 2009, 394, 1903-1909.	1.9	11

#	Article	IF	Citations
199	Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death. Bioorganic and Medicinal Chemistry, 2009, 17, 5139-5145.	1.4	33
200	A new resorufin-based Î±-glucosidase assay for high-throughput screening. Analytical Biochemistry, 2009, 390, 79-84.	1.1	23
201	A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel. Analytical Biochemistry, 2009, 394, 30-38.	1.1	62
202	Multi-Gram Scale Synthesis of FR180204. Journal of Organic Chemistry, 2009, 74, 8870-8873.	1.7	22
203	Screening Automation. Critical Reviews in Combinatorial Chemistry, 2009, , .	0.1	1
204	A Robotic Platform for Quantitative High-Throughput Screening. Assay and Drug Development Technologies, 2008, 6, 637-657.	0.6	126
205	Quantitative High-Throughput Screening Using a Live-Cell cAMP Assay Identifies Small-Molecule Agonists of the TSH Receptor. Journal of Biomolecular Screening, 2008, 13, 120-127.	2.6	59
206	A Cell-Based PDE4 Assay in 1536-Well Plate Format for High-Throughput Screening. Journal of Biomolecular Screening, 2008, 13, 609-618.	2.6	21
207	Compound Management for Quantitative High-Throughput Screening. Journal of the Association for Laboratory Automation, 2008, 13, 79-89.	2.8	72
208	A Miniaturized Glucocorticoid Receptor Translocation Assay Using Enzymatic Fragment Complementation Evaluated with qHTS. Combinatorial Chemistry and High Throughput Screening, 2008, 11, 545-559.	0.6	15
209	Optimization and Validation of Two Miniaturized Glucocerebrosidase Enzyme Assays for High Throughput Screening. Combinatorial Chemistry and High Throughput Screening, 2008, 11, 817-824.	0.6	35
210	Comparison on Functional Assays for Gq-Coupled GPCRs by Measuring Inositol Monophospate-1 and Intracellular Calcium in 1536-Well Plate Format. Current Chemical Genomics, 2008, 1, 70-78.	2.0	32
211	Evaluation of Micro-Parallel Liquid Chromatography as a Method for HTS-Coupled Actives Verification. Assay and Drug Development Technologies, 2007, 5, 815-824.	0.6	4
212	Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13192-13197.	3.3	139
213	N4-Phenyl modifications of N2-(2-hydroxyl)ethyl-6-(pyrrolidin-1-yl)-1,3,5-triazine-2,4-diamines enhance glucocerebrosidase inhibition by small molecules with potential as chemical chaperones for Gaucher disease. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5783-5789.	1.0	30
214	High-throughput screening assays for the identification of chemical probes. Nature Chemical Biology, 2007, 3, 466-479.	3.9	555
215	Fluorescent Proteinâ€Based Cellular Assays Analyzed by Laserâ€Scanning Microplate Cytometry in 1536â€Well Plate Format. Methods in Enzymology, 2006, 414, 566-589.	0.4	29
216	Identification of small molecule antagonists of the human mas-related gene-X1 receptor. Analytical Biochemistry, 2006, 351, 50-61.	1.1	30

#	Article	IF	Citations
217	A Cell-Based Ultra-High-Throughput Screening Assay for Identifying Inhibitors of D-Amino Acid Oxidase. Journal of Biomolecular Screening, 2006, 11, 481-487.	2.6	54
218	Quantitative high-throughput screening: A titration-based approach that efficiently identifies biological activities in large chemical libraries. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 11473-11478.	3.3	733
219	High-Throughput Screening of 11Î²-Hydroxysteroid Dehydrogenase Type 1 in Scintillation Proximity Assay Format. Assay and Drug Development Technologies, 2005, 3, 377-384.	0.6	11
220	A Short-Incubation Reporter-Gene Assay for High-Throughput Screening of Estrogen Receptor-Î± Antagonists. Assay and Drug Development Technologies, 2005, 3, 393-400.	0.6	5
221	Application of Division Arrest Technology to Cell-Based HTS: Comparison with Frozen and Fresh Cells. Assay and Drug Development Technologies, 2005, 3, 17-26.	0.6	36
222	A 1,536-Well cAMP Assay for Gs- and Gi-Coupled Receptors Using Enzyme Fragmentation Complementation. Assay and Drug Development Technologies, 2004, 2, 39-49.	0.6	30
223	High-Throughput Cell-Based Screening Using Scintillation Proximity Assay for the Discovery of Inositol Phosphatase Inhibitors. Journal of Biomolecular Screening, 2004, 9, 132-140.	2.6	10
224	High Throughput Assay Technologies for Ion Channel Drug Discovery. Assay and Drug Development Technologies, 2004, 2, 543-552.	0.6	120
225	Application of Real-Time Cell Electronic Sensing (RT-CES) Technology to Cell-Based Assays. Assay and Drug Development Technologies, 2004, 2, 363-372.	0.6	343
226	Scintillation proximity assay of inositol phosphates in cell extracts: High-throughput measurement of G-protein-coupled receptor activation. Analytical Biochemistry, 2003, 313, 311-318.	1.1	82
227	A Collaborative Screening Program for the Discovery of Inhibitors of HCV NS2/3 cis-Cleaving Protease Activity. Journal of Biomolecular Screening, 2002, 7, 149-154.	2.6	28
228	Characterization of Calcium Channel Binding. Current Protocols in Pharmacology, 2001, 14, Unit1.25.	4.0	0
229	2-Arylindole-3-acetamides. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 865-869.	1.0	17
230	Miniaturization of a Hepatitis C Virus RNA Polymerase Assay Using a â^'102Â°C Cooled CCD Camera-Based Imaging System. Analytical Biochemistry, 2001, 290, 214-220.	1.1	26
231	Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor. Journal of Biological Chemistry, 1998, 273, 15687-15692.	1.6	123
232	Increased Expression of the Cardiac L-type Calcium Channel in Estrogen Receptorâ€“deficient Mice. Journal of General Physiology, 1997, 110, 135-140.	0.9	165
233	Thermodynamic and kinetic aspects of agonist and antagonist binding to 1,4-dihydropyridine receptors. European Journal of Pharmacology, 1991, 208, 137-147.	2.7	6
234	Therapeutic Strategies For Tay-Sachs Disease. Frontiers in Pharmacology, 0, 13, .	1.6	7